Suppr超能文献

我们改变了膜性肾病的结局吗?一项关于免疫抑制治疗作用的倾向评分研究。

Have we changed the outcome in membranous nephropathy? A propensity study on the role of immunosuppressive therapy.

机构信息

Department of Nephrology, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.

出版信息

Clin J Am Soc Nephrol. 2011 Jul;6(7):1591-8. doi: 10.2215/CJN.11001210. Epub 2011 Jun 16.

Abstract

BACKGROUND AND OBJECTIVES

The long-term effect of immunosuppressive therapy (IS) on kidney survival in idiopathic membranous nephropathy (MGN) is debated. The introduction of renin angiotensin blockade, rigorous BP control, and the increasing age at presentation of patients with MGN adds further uncertainty. Given these important changes, we sought to determine whether implementation of IS has altered outcome.

DESIGN, SETTING, PARTICIPANTS, & METHODS: We prospectively evaluated 280 incident MGN patients from three distinct 10-year periods starting from 1975.

RESULTS

We found expected changes in treatment regimens but also variations in age, renal function, severity of proteinuria, and BP at presentation over this time. Outcomes did not differ over time if these significant variations in clinical characteristics were not accounted for across the eras. The effect of IS in the 57 patients treated with currently recommended regimens was assessed using propensity adjustment to address selection bias and the effect of newer, conservative therapies. A propensity score estimating the probability of receiving IS permitted the pairing of 39 treated patients with controls with similar high risk of progression of clinical features. Using this approach, IS was associated not only with remissions in proteinuria but also with substantially improved renal survival.

CONCLUSIONS

The study confirms that patient presenting characteristics and management regimens have changed significantly over time and the natural history of MGN has been altered. A study of propensity-matched patients confirms that current recommendations for IS have improved outcomes in MGN patients at high risk of progression.

摘要

背景和目的

免疫抑制疗法(IS)对特发性膜性肾病(MGN)患者肾脏生存的长期影响存在争议。肾素-血管紧张素阻断剂的引入、严格的血压控制以及 MGN 患者发病年龄的增加进一步增加了不确定性。鉴于这些重要的变化,我们试图确定 IS 的实施是否改变了结局。

设计、设置、参与者和方法:我们前瞻性评估了来自三个不同的 10 年时期的 280 例特发性 MGN 患者,这些时期从 1975 年开始。

结果

我们发现治疗方案发生了预期的变化,但在这段时间内,年龄、肾功能、蛋白尿严重程度和血压在发病时也存在变化。如果不考虑各时期这些临床特征的显著变化,结果在不同时期没有差异。使用倾向评分调整来解决选择偏倚和新的保守治疗方法的影响,评估了目前推荐的治疗方案治疗的 57 例患者中 IS 的作用。倾向评分估计接受 IS 的概率允许将 39 例接受治疗的患者与具有相似临床特征进展高风险的对照组进行配对。采用这种方法,IS 不仅与蛋白尿缓解有关,而且与肾脏生存的显著改善有关。

结论

该研究证实,患者的表现特征和治疗方案在过去的时间里发生了显著变化,MGN 的自然史已经改变。一项倾向评分匹配患者的研究证实,目前推荐的 IS 方案改善了高进展风险的 MGN 患者的预后。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验